Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice

Neurobiology of Aging

Volumn 24, Issue 2, 2003, Pages 245-258

  Gomez Isla, Teresa ^a,d   Irizarry, Michael C ^b   Mariash, Ami ^a   Cheung, Bonnie ^b   Soto, Oscar ^a   Schrump, Stefanie ^a   Sondel, Jesse ^a   Kotilinek, Linda ^a   Day, John ^a   Schwarzschild, Michael A ^b   Cha, Jang Ho J ^b   Newell, Kathy ^b   Miller, David W ^b   Uéda, Kenji ^c   Young, Anne B ^b   Hyman, Bradley T ^b   Ashe, Karen H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Dopamine; Lewy body; Parkinson's disease; Substantia nigra; Synuclein; Transgenic mice; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN A30P; ALPHA SYNUCLEIN A53T; AMINO ACID; DOPAMINE; DOPAMINE RECEPTOR; MARKER; PRION PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; DOPAMINERGIC SYSTEM; DYSTONIA; FRAGMENTATION REACTION; GENE MUTATION; GENE OVEREXPRESSION; GLIOSIS; HAMSTER; HISTOLOGY; HUMAN; IMMUNOREACTIVITY; LEWY BODY; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIGIDITY; SUBSTANTIA NIGRA; TRANSGENE; TRANSGENIC MOUSE; TREMOR;

ALPHA-SYNUCLEIN; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DOPAMINE; ELECTROMYOGRAPHY; FEMALE; GENE EXPRESSION; GLIOSIS; HUMANS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; MOVEMENT DISORDERS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; RNA, MESSENGER; SUBSTANTIA NIGRA; SYNUCLEINS; TYROSINE 3-MONOOXYGENASE;

EID: 0037333642     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00091-X     Document Type: Article

References (51)

1. Arima K., Uéda K., Sunohara N., Hirai S., Izumiyama Y., Tonozuka-Uehara H.et al. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808:1998;93-100.
2. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M.et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152:1998;879-884.
3. Cavalieri B. Geometria degli indivisibili. Torino, Unione Tipografico, Editrice, 1966.
4. Cha J.-H.J., Farrell L.A., Ahmed S.F., Frey A., Ashe K.H., Young A.B.et al. Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol. Dis. 8:2001;90-102.
5. Cha J.-H.J., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W.et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6480-6485.
6. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21:1998;249-254.
7. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4:1998;1318-1320.
8. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97:2000;571-576.
9. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine alpha-synuclein adduct. Science. 294:2001;1346-1349.
10. 3H ]-YM-09151-2 Eur. J. Pharmacol. 199:1991;103-106.
11. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436:1998;309-312.
12. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273:1998;9443-9449.
13. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J.et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22:1999;110-114.
14. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature. 404:2000;394-398.
15. George J.M., Jin H., Woods W.S., Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 15:1995;361-372.
16. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I.et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989.
17. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M. Mutant and wild-type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274:1999;7619-7622.
18. Goldberg M.S., Lansbury P.T. Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease. Nat. Cell Biol. 2:2000;E115-E119.
19. Gomez-Tortosa E., Newell K., Irizarry M.C., Sanders J.L., Hyman B.T. Alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. (Berlin). 99:2000;352-357.
20. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M.et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport. 10:1999;717-721.
21. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., Masliah E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274:1999;28849-28852.
22. Ashe K.H., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
23. Ashe K.H., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W.S.et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 15:1995;1203-1218.
24. Irizarry M.C., Growdon W., Gomez-Isla T., Newell K., George J.M., Clayton D.F.et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57:1998;334-337.
25. Irizarry M.C., Kim T.W., McNamara M., Tanzi R.E., George J.M., Clayton D.F.et al. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55:1996;889-895.
26. Irizarry M.C., McNamara M., Fedorchak K., Ashe K.H., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56:1997;965-973.
27. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A.et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 14:1995;467-475.
28. Jensen P.H., Hager H., Nielsen M.S., Hojrup P., Gliemann J., Jakes R. Alpha-synuclein binds to Tau and stimulates the protein kinase A catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274:1999;25481-25489.
29. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A.et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20:2000;6365-6373.
30. Kahle P.J., Neumann M., Ozmen L., Muller V., Odoy S., Okamoto N.et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159:2001;2215-2225.
31. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S.et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:1998;106-108.
32. Maroteaux L., Scheller R.H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11:1991;335-343.
33. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A.et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287:2000;1265-1269.
34. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M.et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;12245-12250.
35. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J.et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8:2001;535-539.
36. McLean P.J., Kawamata H., Ribich S., Hyman B.T. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275:2000;8812-8816.
37. Morris R. Developments of a water maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 11:1984;47-60.
38. Ozawa T., Okuizumi K., Ikeuchi T., Wakabayashi K., Takahashi H., Tsuji S. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol. (Berlin). 102:2001;188-190.
39. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A.et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
40. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M.et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 77:2001;1181-1184.
41. Richfield E.K., Young A.B., Penney J.B. Properties of D2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. Brain Res. 383:1986;121-128.
42. Rockenstein E., Hansen L.A., Mallory M., Trojanowski J.Q., Galasko D., Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 914:2001;48-56.
43. Scott M.R., Kohler R., Foster D., Prusiner S.B. Chimeric prion protein expression in cultured cells and transgenic mice. Protein Sci. 1:1992;986-997.
44. Serpell L.C., Berriman J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;4897-4902.
45. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 388:1997;839-840.
46. Uéda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M.et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11282-11286.
47. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S.et al. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20:2000;6021-6029.
48. Wakabayashi K., Engelender S., Yoshimoto M., Tsuji S., Ross C.A., Takahashi H. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47:2000;521-523.
49. Wakabayashi K., Hayashi S., Kakita A., Yamada M., Toyoshima Y., Yoshimoto M.et al. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. (Berlin). 96:1998;445-452.
50. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239:1997;45-48.
51. Wilson J.M., Kish S.J. The vesicular monoamine transporter in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 16:1996;3507-3510.